PDCD1 and glioblastoma: For example, a phase I study demonstrated that combination treatment with hypofractionated RT (5 × 6 Gy), the anti-PD-1 antibody pembrolizumab, and the anti-VEGF antibody bevacizumab was well tolerated in GBM patients and induced promising survival results (mOS, 13.4 months; mPFS, 7.9 months) [227].